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Critically ill patients frequently require inotropic and/or vasopressor 
support to treat circulatory shock. Subtypes of circulatory shock 
include hypovolaemic, cardiogenic, obstructive (e.g. pulmonary 
embolus, tension pneumothorax) and distributive (e.g. septic, 
neurogenic) shock. Patients with cardiogenic shock or a cardiogenic 
component to their shock state are frequently treated with 
dobutamine, an agent with positive inotropic effects and a mild 
net vasodilatory effect, an ‘inodilator’.[1] Most other forms of shock 
are treated with noradrenaline or adrenaline. Both these agents 
have positive inotropic and vasoconstrictive effect ‘inopressors’.[1] 
Noradrenaline is recommended as first-line therapy in septic shock. 
However, due to the limited availability of noradrenaline in South 
Africa (SA), adrenaline is frequently used in lieu of the former.[2] 
Clinical experience suggests that mortality in critically ill patients 
increases with increasing doses of inotropes and/or vasopressors. 
Critical care physicians are often faced with determining a threshold 
of inopressor support, above which rescue therapy is required 
or where survival is unlikely. The literature to help to determine 
these thresholds is limited. An inotrope dose is a component of 
the Sequential Organ Failure Assessment (SOFA) score, which has 
been found to correlate with intensive care unit (ICU) mortality.[3,4] The 
cardiovascular component of the score, however, only differentiates 
between a dose of ≤0.1 µg/kg/min or >0.1 µg/kg/min of adrenaline 
or noradrenaline. These doses are relatively low and are not a clinically 
relevant threshold. A few studies have specifically explored the 
relationship between catecholamine dose and patient survival in 
critical care. Benbenishty et al.[5] reported survival of only 4% in 
patients receiving >0.5 µg/kg/min of inotropic support, Jenkins et al.[6] 
found that only 3.3% of patients receiving >100 µg/min of noradrenaline 
survived, Sviri et al.[7] showed a mortality rate of 84% in patients receiving 
>40 µg/min of inotropic support, and Brown et al.[8] reported a mortality 
rate of 83% in patients receiving ≥1 µg/kg/min. In contrast, Auchet et al.[9] 
reported a survival rate of 39.6% in patients receiving >1 µg/kg/min, 
with Döpp-Zemel and Groeneveld[10]noting a similar survival rate 
of 34.5% in patients receiving ≥0.9 µg/kg/min.
The disparate findings presented above make it difficult for physicians 
treating critically ill patients to take evidence-based decisions. This is 
further compounded by the abovementioned studies having been 
conducted in high-income countries, and it is unclear whether the 
results are applicable to low- and middle-income countries. Potential 
differences include those regarding drug availability (e.g. limited 
availability of noradrenaline in SA), ICU bed availability and triage and 
patient profile, including a young age and an increased incidence of 
HIV and sepsis in sub-Saharan Africa and SA specifically.[11-14]
It is therefore important to evaluate the inotrope prescribing 
practices in the SA context, and to establish whether there is an 
association between dose and patient outcome. This will allow for 
improved evidence-based quality of care for critically ill SA patients. 
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Background. Vasoactive and/or inotropic agents are used in the management of patients with circulatory shock. It is a clinical perception 
that mortality in critically ill patients increases with increasing doses of inotropes and/or vasopressors; however, the clinical significance of 
catecholamine doses early in the management of critically ill patients has not been investigated well, especially in the South African (SA) 
context. Arbitrary ‘maximum’ doses of catecholamine therapy are used that are not evidence based. This study will help clinicians by either 
showing that there is no clear cut-off beyond which survival is unlikely or by identifying a dose of inotropic support above which survival 
is unlikely. This article provides clinicians with an evidence base against which to direct their therapy.
Objectives. To describe the inotropic prescribing practices in a heterogeneous population of shocked critically ill patients in a tertiary 
intensive care unit (ICU) in SA, establish an association between inotropic dose and outcome and ascertain the nature of this association.
Methods. This was a retrospective observational study of 189 patients admitted to a multidisciplinary academic ICU. The admission, 
24-hour and maximum inotrope doses were collected and analysed, and these and other biochemical and clinical parameters were evaluated 
as predictors of mortality.
Results. A total of 189 patients met the study inclusion criteria. The overwhelming majority of patients (99%) received adrenaline, with 
only 7% of those requiring inotropes receiving noradrenaline. Median inotrope dose at admission, 24-hour dose and maximum dose in the 
first 24 hours were all significantly higher in non-survivors than survivors. ICU mortality increased with increasing inotrope dose, and an 
inotrope dose ≥60 µg/min on admission was associated with an ICU mortality of 89%, with the same cut-off at 24 hours being associated 
with a mortality of 89%. Survivors at doses >80 µg/min were only noted among trauma patients. 
Conclusions. High early inotrope doses are associated with increasing ICU mortality. The findings highlight the need for further research 
on the clinical use of inotrope dose in risk stratification in the critical care environment. The current results call into question the routine 
provision of high-dose inotropic support in non-trauma patients. 
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Methods
This was a retrospective observational study of patients admitted to a 
multidisciplinary, closed, intensivist-run ICU in a tertiary academic 
hospital that serves the province of KwaZulu-Natal in SA.
All adult (≥18 years) patients requiring inotropic support with 
adrenaline or noradrenaline to maintain a mean arterial pressure 
>70 mmHg within the first 24 hours of ICU admission, were eligible 
for inclusion. The exclusion criteria were as follows: children (age 
<18 years), use of dobutamine, cardiogenic shock/refractory cardiac 
failure or documentation of a significant cardiogenic component in 
the setting of mixed forms of shock. Dobutamine use was excluded 
owing to lack of dose equivalency with the dominant catecholamines 
used in the study ICU, and owing to its drug-specific effects that 
prevent a direct pharmacological comparison between dobutamine 
and adrenaline/noradrenaline. Cardiogenic shock/refractory cardiac 
failure was an exclusion, as dobutamine is the catecholamine of 
choice in this condition. Data collection proceeded backwards from 
the date of ethical approval, with patients admitted from May 2016 to 
June 2018 included in the study.
Based on previous study data, using an alpha of 0.05, a power of 
80% and an anticipated ratio of patients with high-dose:low-dose 
inotropic support of 0.2, a sample size of 112 was calculated.[9] It 
was unclear how appropriate the values used in the sample size 
calculation were for the study ICU (i.e. effect size and enrolment 
ratio) and it was therefore decided to use a sample size of 200 or 
include patients over a 2-year period, whichever came first. This 
would be logistically feasible, while allowing for a margin of safety, 
given the unknown factors discussed above. 
Statistical analysis was performed using SPSS version 25.0 
(IBM Corp., USA) and MedCalc Statistical Software version 18.10.2 
(MedCalc, Belgium).The categorical variables were described as 
percentages and compared using the χ2 test or Fisher’s exact test, 
where appropriate. Continuous data were described using mean and 
standard deviation (SD) when normally distributed, and median and 
interquartile range (IQR) when the distribution was non-Gaussian. 
These data were compared using the independent samples t-test, 
Mann-Whitney U-test or Kruskal-Wallis test, respectively. Receiver 
operating characteristic (ROC) curves were constructed for inotrope 
dose and ICU mortality. The optimal cut-off point for each inotrope 
dose was determined by identifying the points on the curve closest 
to the (0.1) corner. These cut-off points were then combined with 
commonly considered clinical cut-off points, and the performance 
of each cut-off compared by determining the sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), 
positive likelihood ratio (PLR), and negative likelihood ratio (NLR). 
Where appropriate, the areas under the ROC curve (AUC) was 
compared using the method described by DeLong et al.[15]
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Results
The derivation of the study cohort is shown in Fig. 1. The final study 
population included 189 patients who required inotropic support 
with adrenaline and/or noradrenaline during the first 24 hours of 
ICU admission. 
Table 1 shows the baseline demographic, organ dysfunction, 
outcome and inotrope data for the cohort, and provides univariate 
analyses between these variables and ICU mortality. Patients were not 
classified according to the ‘type’ of shock they exhibited, with those 
with suspected cardiogenic shock being excluded from the analysis; 
the included patients comprised mainly hypovolaemic/haemorrhagic 
shock and/or septic shock. In all cases, noradrenaline was the second 
inotrope. 
The admission, 24-hour and maximum inotrope doses were all 
significantly higher in non-survivors than survivors (Table 1). Fig. 2 
shows the ROC curve analyses for the abovementioned inotrope 
doses and ICU mortality. The AUC for the admission inotrope dose 
was 0.67 (95% confidence interval (CI) 0.59 - 0.76; p<0.001), for the 
24-hour inotrope dose 0.76 (95% CI 0.69 - 0.84; p<0.001) and for the 
maximum inotrope dose within 24 hours 0.75 (95% CI 0.68 - 0.83). 
The AUC for the admission inotrope dose was significantly lower 
than for the 24-hour (p=0.042) and maximum (p=0.021) inotrope 
doses.
The ROC curves were used to select potential optimum cut-off 
points for inotrope doses; their performance and common clinical 
cut-off points are presented in Table 2. For a cut-off of 60 µg/min, the 
PPV for mortality approaches 90% for both admission and 24-hour 
inotropic requirements.
Table 3 shows the subgroup analyses for inotrope doses and ICU 
outcome according to the primary admission diagnosis. Median 
inotrope doses were significantly higher in non-survivors at all points 
and in all subgroups, except for trauma patients on admission.
Figs 3, 4 and 5 illustrate plots of inotrope doses and ICU outcomes 
by primary diagnosis. The maximum inotrope dose in survivors with 
non-communicable disease was 67 µg/min, 80 µg/min in sepsis and 
143 µg/min in trauma.
Discussion
The ICU at which the study took place treats a notably young 
cohort of patients with a high incidence of trauma and infectious 
disease.[3] The cohort had a high severity of illness, as evidenced by 
the admission SOFA score, and consequently a high mortality rate. 
The study included a heterogenous group of medical, surgical and 
obstetric patients with a spectrum of infectious, traumatic and non-
communicable primary pathological conditions. Patients were not 
classified according to type of shock due to the many contributing 
factors to shock in any patient; however, if a significant cardiogenic 
component was known or suspected, such patients were excluded 
Patients included
• n=189
   • Survived, n=96 (50.8%)
   • Died, n=93 (49.2%)
Patients with shock during rst 24 hours of ICU admission
• n=217
Patients excluded
• Age: <18 years, n=12
• Dobutamine use, n=14
• Transferred to another ICU (no outcome available), n=2
Fig. 1. Derivation of study cohort. (ICU = intensive care unit.)
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from the study. The dominant inotrope used 
was adrenaline, with noradrenaline being 
used in a small subset of patients, which 
reflects its limited availability in SA. 
It was expected that for patients with 
a poor prognosis, the treating intensivist 
may have limited the maximum inotrope 
dose, which would have introduced bias 
into the study. However, there were written 
instructions to limit inotropic support for 
only 3 patients during the first 24 hours of 
admission, and all survived to ICU discharge. 
This possibly reflects a reluctance among 
the treating physicians to limit inotropic 
support early in the course of critical illness 
until a trial period of active haemodynamic 
optimisation has been completed.















Female, n (%) 95 (50.3) 47 (49.0) 48 (51.6) 0.715
Admission discipline, n (%) O&G 19 (10.1) 12 (12.5) 7 (7.5) 0.519
Medical 76 (40.2) 38 (39.6) 38 (40.9) 
Surgical 94 (49.7) 46 (47.9) 48 (51.6) 
Primary diagnosis, n (%) Sepsis 68 (36.0) 28 (29.2) 40 (40.0) 0.088
Trauma 47 (24.9) 29 (30.2) 18 (19.4) 
Non-communicable 74 (39.2) 39 (40.6) 35 (37.6) 
Postoperative, n (%)   103 (54.5) 56 (58.3) 47 (50.5) 0.282
Mechanical ventilation (1st 24 hours), n (%) 189 (100) 96 (100) 93 (100) 
RRT (1st 24 hours), n (%) 16 (8.5) 6 (6.3) 10 (10.8) 0.266
Death within 24 hours, n (%) 20 (10.6) 0 (0) 20 (21.5) <0.001
Discharge within 24 hours, n (%) 1 (0.5) 1 (1.0) 0 (0) 0.324
ICU LOS   4.0 (2.0 - 6.0) 4.0 (3.0 - 7.0) 3.0 (1.0 - 5.0) <0.001














AKI within first 24 hours, n (%) 77 (41.0) 31 (32.3) 46 (50.0) 0.014
Inotrope 1 on admission, n (%) Adrenaline 184 (97.4) 93 (96.9) 91 (97.8) 0.857
Noradrenaline 2 (1.1) 1 (1.0) 1 (1.1) 
Nil 3 (1.6) 2 (2.1) 1 (1.1) 
Use of second inotrope on admission, n (%) 10 (5.3) 0 (0) 10 (10.8) 0.001
Inotrope 1 at 24 hours, n (%) Adrenaline 148 (88.1) 80 (84.2) 68 (93.2) 0.062
Noradrenaline 1 (0.6) 0 (0) 1 (1.4) 
Nil 19 (11.1) 15 (15.8) 4 (5.5) 
Use of second inotrope at 24 hours, n (%) 10 (6.0) 2 (2.1) 8 (11.0) 0.016























Non-escalation or withdrawal of inotropic 
support during first 24 hours, n (%)
3 (1.6) 3 (3.1) 0 (0) 0.086
ICU = intensive care unit; IQR = interquartile range; O&G = obstetrics and gynaecology; RRT = renal replacement therapy; LOS = length of stay; SOFA = Sequential Organ Failure Assessment; 
AKI = acute kidney injury.














0               0.2              0.4              0.6              0.8             1.0
Admission inotrope dose, µg/min 
24-hour inotrope dose, µg/min 
Maximum inotrope dose, µg/min 
Reference line
Fig. 2. Receiver operating characteristic curve for inotrope dose and intensive care unit mortality.
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Table 2. Inotropic cut-off analyses for ICU mortality*
Timing of inotropic 
support
Inotrope dose 
cut-off, µg/min Sensitivity, % Specificity, % NPV, % PPV, % PLR NLR
Admission 7 88.2 27.1 70.3 53.9 1.21 0.44
13 84.9 33.3 69.6 55.2 1.27 0.45
21 62.4 62.5 63.2 61.7 1.66 0.60
25 60.2 69.8 64.4 65.9 1.99 0.57
40 38.7 86.5 59.3 73.5 2.86 0.71
47 31.2 93.8 58.4 82.9 4.99 0.73
60 25.8 96.9 57.4 88.9 8.26 0.77
80 10.8 99.0 53.4 90.9 10.32 0.90
100 6.5 100 52.5 100  -† 0.94
24 hours  7 83.6 53.2 80.6 58.1 1.79 0.31
13 72.6 62.8 74.7 60.2 1.95 0.44
21 65.8 79.8 75.0 71.6 3.25 0.40
25 58.9 83.0 72.2 72.9 3.46 0.50
40 47.9 92.6 69.6 83.3 6.44 0.56
47 38.4 93.6 66.2 82.4 6.01 0.66
60 34.2 96. 65.5 89.3 10.73 0.68
80 21.9 97.9 61.7 88.9 10.30 0.80
100 15.1 98.9 60.0 91.7 14.16 0.86
Maximum dose  7 96.8 10.4 76.9 51.1 1.08 0.31
13 94.6 19.8 79.2 53.3 1.18 0.27
21 83.9 44.8 74.1 59.5 1.52 0.36
25 81.7 49.0 73.4 60.8 1.60 0.37
40 71.0 69.8 71.3 69.5 2.35 0.42
47 64.5 80.2 70.0 75.9 3.26 0.44
60 53.8 89.6 66.7 83.3 5.16 0.52
80 32.3 95.8% 59.4 88.2 7.74 0.71
100 21.5 97.9 56.3 90.9 10.32 0.80
ICU = intensive care unit; NPV = negative predictive value; PPV = positive predictive value; PLR = positive likelihood ratio; NLR = negative likelihood ratio.
*Analyses are for dose ≥ the cut-off dose. 
†Cannot be calculated.
Table 3. Comparison of median inotrope dose according to primary diagnosis and ICU outcome























































ICU = intensive care unit; IQR = interquartile range.
*Comparing median inotrope dose between sepsis, trauma and non-communicable diagnoses (Kruskal-Wallis test). 
†Comparing median inotrope dose between survivors and non-survivors (Mann-Whitney U-test).
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There was a statistically significant differ-
ence in the median inotrope dose between 
survivors and non-survivors for admission, 
24-hour and maximum inotrope doses, 
which was an anticipated finding. The 
magnitude of the difference appeared more 
marked for 24-hour and maximum inotrope 
doses than for admission inotrope dose. 
Similarly, ROC curve analyses showed that 
inotrope dose was significantly associated 
with ICU mortality, with reasonable 
predic tive accuracy. The performance of 
24-hour and maximum inotrope doses was 
significantly better than for the admission 
inotrope dose.
While statistically significant, these 
findings do not necessarily provide the 
practising clinician with clinically relevant 
data. To this end, the performance of various 
inotropic cut-off points was evaluated (see 
Methods above) (Table 2). The NPV of 
low doses of inotropic support (<13 µg/min) 
is reasonably high (≥70%), indicating that 
these patients are likely to survive ICU 
admission. This is particularly true if the 
inotrope dose remains low, with an NPV 
of 80.6% if inotropic support at 24 hours 
is <7 µg/min. However, the main clinical 
challenge for intensive care physicians 
is predicting which patients are unlikely 
to survive ICU stay. This is especially 
relevant in resource-limited settings, due 
to the scarcity and cost of critical care. In 
this regard, the PPV for ICU mortality of 
inotropic support approaches 90% for both 
admission and 24-hour inotrope doses, with 
similar findings for a maximum inotrope 
dose ≥80 µg/min. Similarly, the specificity 
for an admission or 24-hour cut-off of 
60 µg/min is 96.9% and 96.8%, respectively, 
implying a very low false-positive rate for 
ICU mortality. 
With a mortality rate approaching 90% 
for an admission or 24-hour inotrope dose 
≥60 µg/min, the clinical and ethical question 
that needs to be considered is whether this is 
an appropriate ceiling for inotropic support. 
A clear maximum recommended dose of 
inotropic support would allow clinicians 
to triage patients on admission, or at least 
at 24 hours after admission. This would 
reduce patient exposure to unnecessary 
artificial life-sustaining therapy and reduce 
inappropriate utilisation of critical care 
resources. The value judgement to be made 
is whether 90% mortality provides adequate 
clinical certainty. For many clinicians, this 
would not be adequate certainty, with a 
single inotrope dose therefore being unlikely 
to replace clinical judgement. A counter 
argument is that a strong case would need to 






















Survived     Died Survived     Died Survived     Died
ICU outcome ICU outcome ICU outcome
Non-communicable                       Trauma                                 Sepsis
Fig. 3. Plots comparing admission inotrope dose and ICU outcome by primary diagnosis. (ICU = 
intensive care unit.)
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Fig. 4. Plots comparing 24-hour inotrope dose and ICU outcome by primary diagnosis. (ICU = 
intensive care unit.)






















Survived     Died Survived     Died Survived     Died
ICU outcome ICU outcome ICU outcome
Sepsis                                    Trauma                   Non-communicable
679       July 2021, Vol. 111, No. 7
RESEARCH
to continue with >60 µg/min of inotropic support. With only a 10% 
chance of survival, it could be argued that ongoing artificial life-
sustaining therapy is not ethically appropriate. 
Direct comparisons with other studies in the field are difficult 
owing to differences in patient population and study methodology. 
The findings of this study are, however, broadly compatible with those 
of Benbenishty et al.,[5] Jenkins et al.,[6] Sviri et al.[7] and Brown et al.,[8] 
but show higher mortality than those of Auchet et al.[9] and Döpp-
Zemel and Groeneveld.[10] These findings highlight the difficulties of 
applying studies from other settings to a specific clinical population 
and illustrate the importance of conducting locally relevant research. 
Subgroup analysis suggests clinically relevant differences in 
response to inotropic support according to the primary pathology. 
While no survivors were noted who had been administered inotrope 
doses >80 µg/min in sepsis and non-communicable disease, survival 
up to the maximum inotrope dose of 143 µg/min was seen in 
trauma. This is most likely due to trauma patients being younger and 
having fewer comorbidities, and most importantly, having a readily 
reversible underlying pathology. These subgroup differences should 
be considered the limitation of inotropic support, while more liberal 
use of higher thresholds in trauma patients is recommended.
Study strengths and limitations
This study has numerous strengths, most notably that it is the first 
such study in a resource-limited setting and in sub-Saharan Africa. It 
also explored early inotrope dose, the use of clinically relevant cut-off 
points to improve its clinical utility and potentially clinically relevant 
subgroup differences. 
The study limitations include the retrospective nature and 
relatively small population size. The classification of the patient’s 
shock state was particularly difficult from retrospective notes and, 
therefore, other than excluding patients with an apparent cardiogenic 
component, further categorisation of the shock state was not used. 
The single-centre nature of the study also limits the generalisability 
of the results. For this reason, a larger prospective multicentre study 
exploring these issues is strongly advised. The other factor that may 
have introduced bias into the study is the limitation of inotrope dose 
by the treating physician. While this was noted in only 3 patients 
(all of whom survived their ICU admission) due to the retrospective 
nature of the study, the limitations of inotropic support may have 
occurred, but were not documented in the clinical notes. The kinetics 
of inotropic support were not evaluated, and some factors, such as 
duration of peak inotropic support and changes in inotropic support, 
may have significant prognostic implications and warrant further 
investigation.
Conclusions
The study found early inotropic dose to be significantly associated 
with ICU mortality. There was also a statistically significant difference 
in median inotrope dose between survivors and non-survivors for 
admission, 24-hour and maximum inotrope doses. Low doses of 
inotropic support (<13 µg/min) are associated with high ICU survival 
(≥70%), while high doses of inotropic support (≥ 60 µg/min) are 
associated with a mortality approaching 90% for both admission 
and 24-hour inotrope doses, with similar findings for a maximum 
inotrope dose ≥80 µg/min. These findings suggest that early inotrope 
dose may be useful in ICU risk prediction. The results also suggest 
that high doses of inotropic support in patients with sepsis and 
non-communicable disease are unlikely to be beneficial, but more 
appropriate in the acute phase of trauma. Given the high volume of 
young patients who require ICU support in SA, further studies to 
validate these findings are recommended. 
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